glp 1 gip dual agonist GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes GLP-1/GIP Dual Receptor Agonist -
Description
Physician confidence is rising, and payer coverage is expanding as obesity therapies are increasingly treated as long-term metabolic treatments
GLP-1RAs attenuate the activation and recruitment of macrophages into the endothelium [63]
The global obesity GLP-1 market size accounted for USD 8.21 billion in 2025 and is predicted to increase from USD 10.12 billion in 2026 to approximately USD 66.57 billion by 2035, expanding at a CAGR of 23.28% from 2026 to 2035
These trials are mostly based on composite reductions in MACEs (similar to the original ELIXA trial endpoint)
Thus, in addition to a comprehensive approach encompassing multidisciplinary risk factors (dyslipidaemia, hypertension, obesity, smoking, etc.) [8, 9], considering "what drugs to use to lower blood glucose" by selecting hypoglycaemic agents with evidence-based cardiorenal protective effects, according to patient background and risk status is increasingly important [10]
Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels
